2018 was a top year for clinical trials for depression
Looking at depression clinical trials in the database with a start date from 2015 to...
Read More...
Trending menu:
-
![]()
Celldex stops Phase Ib/II trial in melanoma due to GI toxicities after enrolling three patients
The study had enrolled three out of its 10-patient target when it was stopped, a...
Read More...
-
![]()
Amgen’s AMG510 combo exploration in colorectal cancer tumours poised for late 2019, early 2020
The theory behind combining AMG510 with a MEK inhibitor in CRC is that together they...
Read More...
-
![]()
UCB to conduct bridging study of UCB0107 in progressive supranuclear palsy this year
The bridging study will be necessary to provide the safety and pharmacokinetic data needed to...
Read More...
-
![]()
Pfizer unveils top-line Phase III results for abrocitinib study
Atopic dermatitis is a chronic skin disease characterised by inflammation and skin barrier defects that...
Read More...
-
![]()
KalVista’s hereditary angioedema treatment draws uncertainty
HAE is characterised by recurrent episodes of severe swelling (angioedema). The most frequent areas of...
Read More...
-
![]()
Taltz knocks down Tremfya in head-to-head trial in psoriasis patients
Patients treated with Taltz demonstrated statistically significantly higher improvements than those treated with Tremfya as...
Read More...
-
![]()
ESMO 2019: Delegates told refractory metastatic renal cell carcinoma is an unmet need with great growth potential
According to expert opinion, 20─30% of patients with stage I–III localised tumours will relapse after...
Read More...
-
![]()
Zensun’s Neucardin HF drug fast-tracked by FDA
Zensun’s Neucardin HF drug is fast-tracked by the FDA. Neucardin is a recombinant human neuregulin-1...
Read More...
-
![]()
ESMO 2019: Research questions whether high costs of new oncology treatments are associated with added clinical benefits
Two studies presented at the European Society of Medical Oncology indicated that many new anti-cancer...
Read More...
